A recent study published in the Journal for Immunotherapy of Cancer has revealed a promising new approach for the treatment of glioblastoma (GBM), an aggressive and incurable form of primary brain cancer.
Glioblastoma is the most frequent and aggressive primary brain cancer in adults, and patients can expect to live shorter than 2 years, regardless of therapy. The cancer can be treated with CAR T cells, but many patients develop resistance because tumors mutate or delete the antigens recognized by the T cells, while the tumor microenvironment suppresses T-cell activity.
Myosin Therapeutics Inc. has obtained IND clearance by the FDA for MT-125. A phase I study will evaluate MT-125 in combination with standard-of-care radiation in patients with newly diagnosed IDH wild type, MGMT unmethylated glioblastoma.
Glioblastoma is the most common and aggressive malignant brain tumor in adults. Although microtubule-targeting agents (MTAs) are among the most widely used first-line therapies in cancer, their efficacy in glioblastoma is limited by poor penetration of the blood–brain barrier.
Glioblastoma (GBM) is an aggressive cancer from the CNS usually characterized by a very bad prognosis. It is known that around 30%-35% of patients with GBM develop epilepsy as a comorbidity of the disease.
Rznomics Inc. scored a potential ₩1.9 trillion (US$1.35 billion) global license option agreement with Eli Lilly and Co. to codevelop a novel RNA editing gene therapy to treat hereditary hearing loss.
Oncolytic viral therapy offers new avenues in anticancer treatment, and two herpes simplex virus (HSV)-1-based virotherapies have recently gained approval for the treatment of advanced melanoma and recurrent glioblastoma.
Rznomics Inc. scored a potential ₩1.9 trillion (US$1.35 billion) global license option agreement with Eli Lilly and Co. to codevelop a novel RNA editing gene therapy to treat hereditary hearing loss.
Telix Pharmaceuticals Ltd.’s glioblastoma theranostic, TLX-101, is showing promising overall survival in a phase II trial in recurrent high-grade glioma. The targeted radiation therapy, combined with external beam radiation therapy, demonstrated a median overall survival of 12.4 months from treatment initiation and 32.2 months from initial diagnosis. The results significantly outperform the 9.9-month median survival typically observed with radiation therapy alone in recurrent glioblastoma patients.
